Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

J Cancer 2020; 11(24):7302-7311. doi:10.7150/jca.49554 This issue Cite

Research Paper

Erzhu Jiedu decoction ameliorates liver precancerous lesions in a rat model of liver cancer

Yang Cheng1,2,✉, Tianyang Chen2, Jianjie Chen1,2

1. Department of liver disease, Hospital for Infectious Diseases of Pudong District, Shanghai 201299, P.R. China
2. Institute of liver disease, Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, P.R. China

✉ Corresponding author: Dr. Yang Cheng, Department of liver disease, Hospital for Infectious Diseases of Pudong District, No.46 East Huaxia Road, Shanghai 201299, P.R. China. E-mail: chengyangedu.cn.

Citation:
Cheng Y, Chen T, Chen J. Erzhu Jiedu decoction ameliorates liver precancerous lesions in a rat model of liver cancer. J Cancer 2020; 11(24):7302-7311. doi:10.7150/jca.49554. https://www.jcancer.org/v11p7302.htm
Other styles

File import instruction

Abstract

Precancerous lesions are the intermediate stage in the development of liver cancer from cirrhosis. Early intervention measures can effectively prevent the occurrence of liver cancer and prolong the lives of patients, resulting in greater economic effects. Erzhu Jiedu decoction (EJD) is a semiempirical formula that is used in the treatment of cirrhosis and liver cancer according to the academic philosophy of “Preventive treatment of disease” and has achieved good curative effects in clinical practice. The purpose of this study was to investigate the effect of EJD on liver precancerous lesions induced by diethylnitrosamine (DEN) in rats. The results showed that EJD improved the general conditions (body weight, ALT, AST, and GGT) and reduced the number of precancerous lesions in the rat model. Notably, the medium dose of EJD (1.05 g/kg) had better treatment effects than the low dose of EJD, and the high dose of EJD did not further improve the liver lesions compared to the medium dose of EJD. Moreover, EJD effectively reduced the DEN-induced GST-Pi, AFP, CK19, c-Myc, and Ki67 protein expression in liver precancerous tissues. Interestingly, EJD significantly reduced YAP and TAZ mRNA expression in the liver precancerous lesions. Collectively, EJD protects against in the initiation of liver cancer and the regulation of c-Myc and Hippo signaling pathways may be the underlying mechanism.

Keywords: Erzhu Jiedu Decoction, Hepatocellular Carcinoma, Diethylnitrosamine, Liver Precancerous lesions, Traditional Chinese medicine

Citation styles

APA
Cheng, Y., Chen, T., Chen, J. (2020). Erzhu Jiedu decoction ameliorates liver precancerous lesions in a rat model of liver cancer. Journal of Cancer, 11(24), 7302-7311. https://doi.org/10.7150/jca.49554.

ACS
Cheng, Y.; Chen, T.; Chen, J. Erzhu Jiedu decoction ameliorates liver precancerous lesions in a rat model of liver cancer. J. Cancer 2020, 11 (24), 7302-7311. DOI: 10.7150/jca.49554.

NLM
Cheng Y, Chen T, Chen J. Erzhu Jiedu decoction ameliorates liver precancerous lesions in a rat model of liver cancer. J Cancer 2020; 11(24):7302-7311. doi:10.7150/jca.49554. https://www.jcancer.org/v11p7302.htm

CSE
Cheng Y, Chen T, Chen J. 2020. Erzhu Jiedu decoction ameliorates liver precancerous lesions in a rat model of liver cancer. J Cancer. 11(24):7302-7311.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use